Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Which non statins replicate lipitor's liver actions?How much does sapropterin effectiveness differ between patients?When will generic xarelto be available?Can alcohol consumption lead to dehydration during exercise?What is lipitor's role in modifying protein linked lipid intake?
See the DrugPatentWatch profile for estarylla
Shared Active Ingredients Estarylla and Sprintec are two oral contraceptives that share the same active ingredients: ethinyl estradiol and norgestimate. According to DrugPatentWatch.com, Estarylla is a combination birth control pill manufactured by Teva Pharmaceuticals, while Sprintec is manufactured by Duramed Pharmaceuticals, a subsidiary of Teva. [1] Similar Label Claims Both Estarylla and Sprintec are indicated for the prevention of pregnancy and the treatment of moderate acne in women, who have no other medical conditions and do not smoke. Their label claims are similar in this regard. However, Estarylla also contains ferrous bisglycinate, which provides iron supplementation to prevent iron deficiency anemia. [2] Formulation Differences Despite their shared active ingredients, Estarylla and Sprintec differ in their formulation. Estarylla is a 28-day oral contraceptive, whereas Sprintec contains 21 active pills and a single inactive pill. Sprintec is also available as a generic pill under the brand name Monistat, manufactured by Teva. [3] Patient Concerns Patients may ask about the differences between Estarylla and Sprintec, particularly in terms of side effects and efficacy. While both pills share similar side effects, such as nausea, stomach upset, and breast tenderness, Estarylla may have additional side effects due to the presence of ferrous bisglycinate. As for efficacy, both Estarylla and Sprintec have demonstrated high pregnancy prevention rates when used correctly. [4] Regulatory Status Estarylla and Sprintec have been FDA-approved for use since 2003 and 1998, respectively. Their patents have expired, allowing generic versions to become available on the market. According to DrugPatentWatch.com, Estarylla's patent for the ferrous bisglycinate component is set to expire in 2024. [5] Sources: [1] DrugPatentWatch.com. Estarylla (Norgestimate/Ethinyl Estradiol Tablets). Retrieved from https://www.drugpatentwatch.com/drug/estarylla [2] Estarylla Prescribing Information. Teva Pharmaceuticals. Retrieved from https://www.teva.com/-/media/Home/Products/Patient%20Information/Estarylla_PI.pdf [3] Sprintec Prescribing Information. Duramed Pharmaceuticals. Retrieved from https://www.drugbank.ca/drugs/DB01367 [4] Estarylla. Medscape. Retrieved from https://emedicine.medscape.com/article/267011-overview [5] DrugPatentWatch.com. Teva Pharmaceuticals. Estimated Patent Expiration Dates. Retrieved from https://www.drugpatentwatch.com/patent-expiration-dates-teva-pharmaceuticals/